As STAT3 inhibitors have not been clinically approved for cancer therapy due to their relatively low potency or nonselective toxicity or both [51], we used pulvomycin, a STAT3 inhibitor isolated from marine-derived actinomycetes, to treat this aggressive type of cancer. Here, STAT3 is linked to cancer.